"IGG is a regional medical practice comprised of board certified private practice gastroenterologists and allied professionals. We are dedicated to improving the health of our patients by providing the highest quality gastrointestinal care utilizing evidence-based medicine in a safe, compassionate manner, following clinical standards as determined by available scientific knowledge, best practice and innovative treatment."

During the past decade, IL Gastroenterology Group conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 10 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IL Gastroenterology Group" #1 sponsor was "Shire" with 5 trials, followed by "Pfizer" with 4 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored, "Galapagos NV" with 2 trials sponsored and "Phathom Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IL Gastroenterology Group" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator and "Gilead Sciences" with 2 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "IL Gastroenterology Group" are "Ulcerative Colitis" (7 trials), "Crohn's Disease" (6 trials), "Crohn's Disease (CD)" (1 trials), "Erosive Esophagitis" (1 trials) and "Gastroesophageal Reflux Disease (GERD)" (1 trials). Many other conditions were trialed in "IL Gastroenterology Group" in a lesser frequency.

Most popular intervention types in "IL Gastroenterology Group" are "Drug" (15 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Etrasimod" (5 trials), "Ontamalimab" (4 trials), "Filgotinib" (2 trials) and "Lansoprazole" (2 trials). Other intervention names were less common.

The vast majority of trials in "IL Gastroenterology Group" are 16 trials for "All" genders.

Currently, there are NaN active trials in "IL Gastroenterology Group". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in IL Gastroenterology Group, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in IL Gastroenterology Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

IL Gastroenterology Group has several departments that took part in Clinical trials: "Northwest Gastroenterologists, S.C." - 14 trials